- Home
- CNMD vs CNTA Comparison
CNMD vs CNTA Comparison
Compare CNMD & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNMD
- CNTA
- Stock Information
- Founded
- CNMD 1970
- CNTA 2020
- Country
- CNMD United States
- CNTA United Kingdom
- Employees
- CNMD N/A
- CNTA N/A
- Industry
- CNMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- CNMD Health Care
- CNTA Health Care
- Exchange
- CNMD Nasdaq
- CNTA Nasdaq
- Market Cap
- CNMD 2.2B
- CNTA 2.3B
- IPO Year
- CNMD 1987
- CNTA 2021
- Fundamental
- Price
- CNMD $68.65
- CNTA $17.16
- Analyst Decision
- CNMD Buy
- CNTA Strong Buy
- Analyst Count
- CNMD 6
- CNTA 7
- Target Price
- CNMD $82.83
- CNTA $23.71
- AVG Volume (30 Days)
- CNMD 428.8K
- CNTA 705.7K
- Earning Date
- CNMD 01-29-2025
- CNTA 11-12-2024
- Dividend Yield
- CNMD 1.17%
- CNTA N/A
- EPS Growth
- CNMD 127.53
- CNTA N/A
- EPS
- CNMD 4.22
- CNTA N/A
- Revenue
- CNMD $1,288,116,000.00
- CNTA $6,853,000.00
- Revenue This Year
- CNMD $6.69
- CNTA N/A
- Revenue Next Year
- CNMD $7.53
- CNTA N/A
- P/E Ratio
- CNMD $16.26
- CNTA N/A
- Revenue Growth
- CNMD 10.23
- CNTA N/A
- 52 Week Low
- CNMD $61.05
- CNTA $6.65
- 52 Week High
- CNMD $114.80
- CNTA $18.97
- Technical
- Relative Strength Index (RSI)
- CNMD 39.61
- CNTA 50.89
- Support Level
- CNMD $71.28
- CNTA $16.02
- Resistance Level
- CNMD $72.49
- CNTA $18.12
- Average True Range (ATR)
- CNMD 2.78
- CNTA 1.08
- MACD
- CNMD -0.72
- CNTA -0.08
- Stochastic Oscillator
- CNMD 6.11
- CNTA 41.42
About CNMD CONMED Corporation
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.